The Evidence-Based Guide to Antipsychotic Medications is designed to provide both clinicians and residents with focused, comprehensive, and clinically relevant information regarding the use of antipsychotic medications to treat a broad range of psychiatric conditions -- from mood and anxiety disorders to substance abuse, personality disorders, and schizophrenia. The volume editor is a renowned psychiatrist and author with more than 25 years of experience in both clinical and research settings diagnosing and treating patients with mood and psychotic disorders. In addition, each of the volume's 13 contributors is an expert with many years of clinical experience to draw on.The book is down-to-earth and reader-friendly and is structured for maximal utility in both coverage and format: Key Clinical Points cap each chapter, synthesizing and summarizing the knowledge you can take away, and serving both as a refresher for those using the book as a reference and as a study aid to master the material. Both FDA-approved and off-label use of antipsychotic medications are addressed, reflecting the reality of clinical practice on the front lines. Use of antipsychotic medications in both the pediatric and geriatric populations, a potentially controversial subject, is addressed in a nonsensational, straight-forward manner. The Appendixes provide a wealth of information in tabular format, including drug tables (names, strengths, formulations, pharmacokinetics, and dosing); advice on initiating and monitoring antipsychotic medications; common side effects and their management; and special considerations for use during pregnancy and breastfeeding. The Evidence-Based Guide to Antipsychotic Medications is the first in a new series that strives to take evidence-based psychiatry from gold standard to standard practice. Scientifically up-to-date and rigorous, yet accessible and easy to understand, this volume stands alone as an indispensable resource on the topic.
Concepts are illustrated by full-color images that will be familiar to all readers of Stahl's Essential Psychopharmacology, 3rd Edition and The Prescriber's Guide.
Clinicians recognize that monitoring psychotropic levels provides invaluable information to optimize therapy and track treatment adherence, but they lack formal training specifically focused on the use of plasma antipsychotic levels for these purposes. As new technologies emerge to rapidly provide these results, the opportunity to integrate this information into clinical care will grow. This practical handbook clarifies confusing concepts in the literature on use of antipsychotic levels, providing clear explanations for the logic underlying clinically relevant concepts such as the therapeutic threshold and the point of futility, and how these apply to individual antipsychotics. It offers accessible information on the expected correlation between dosages and trough levels, and also provides a clear explanation of how to use antipsychotic levels for monitoring oral antipsychotic adherence, and methods to help clinicians differentiate between poor adherence and variations in drug metabolism. An essential resource for psychiatrists, psychiatric nurse practitioners, and mental health professionals worldwide.
The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.
This is a spin-off from Stephen M. Stahl's new, completely revised and updated version of his much-acclaimed Prescriber's Guide, covering drugs to treat depression.
Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr Stephen M. Stahl has revised chapters covering antipsychotics and mood stabilizers for this edition. More than one-third longer than the previous edition it is essential reading for professionals treating psychosis and students learning the mechanisms of drug reactions. It includes advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. The fully revised text is complemented by many new illustrations and enhanced to reflect new knowledge and topics covered in the previous edition. Intended as a primer text covering all aspects of treatment for psychosis and related conditions, this concise volume can nevertheless be read cover to cover by experts and novices alike. Accreditation and Credit Designation Statements The Neuroscience Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Neuroscience Education Institute designates this educational activity for a maximum of 90.0 AMA PRA Category 1 Credits(tm). Physicians should only claim credit commensurate with the extent of their participation in the activity. Sponsorship Information Sponsored by Neuroscience Education Institute Support This activity is supported solely by the sponsor. Neither the Neuroscience Education Institute nor Stephen M. Stahl, MD, PhD has received any funds or grants in support of this educational activity.
Many people consider stopping their psychiatric medications, but prescribers may not know how to do this in a collaborative, systematic way. This book describes the ins and outs of how clinicians can work closely with their patients to consider whether or not to try decreasing medications. It outlines the how and when, and gives recommendations on what the prescriber and patient may encounter along the way.